Media Room

 

 

Latest News Releases
Oct 16, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for...

Oct 7, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and...

Oct 2, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer...

More »

Multimedia Libraries
Media Contacts
Dan Budwick
Pure Communications, Inc.
Media@purecommunications...

More »

Follow Us on LinkedIn
Follow Us on Twitter


 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide